Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00020605
Status:
UNKNOWN
Last Update Posted:
2018-12-13
First Post:
2001-07-11
Brief Title:
Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain
Sponsor:
Dana-Farber Cancer Institute
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-controlled Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-malignant Pain or Malignant Pain
Status:
UNKNOWN
Status Verified Date:
2001-10
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Naloxone may be effective in treating constipation that may be caused by opioid pain medications such as morphine
PURPOSE Phase III trial to determine the effectiveness of naloxone in relieving constiption in patients who are receiving opioids for chronic pain
PURPOSE Phase III trial to determine the effectiveness of naloxone in relieving constiption in patients who are receiving opioids for chronic pain
Detailed Description:
OBJECTIVES I Assess the long-term safety and efficacy of oral naloxone in treating opioid-induced constipation in patients with chronic malignant or non-malignant pain
OUTLINE This is a multicenter study Patients receive oral naloxone twice daily Each patient receives an escalating dose until the minimum effective dose or the maximum dose allowed is reached The minimum effective dose is defined as the dose at which a patient has at least 4 bowel movements within 7 days Patients receive the minimum effective dose for 7 days and then continue long-term treatment for a maximum of 72 weeks Patients receiving the maximum dose allowed with fewer than 4 bowel movements per week will discontinue study therapy
PROJECTED ACCRUAL Approximately 600 patients will be accrued for this study
OUTLINE This is a multicenter study Patients receive oral naloxone twice daily Each patient receives an escalating dose until the minimum effective dose or the maximum dose allowed is reached The minimum effective dose is defined as the dose at which a patient has at least 4 bowel movements within 7 days Patients receive the minimum effective dose for 7 days and then continue long-term treatment for a maximum of 72 weeks Patients receiving the maximum dose allowed with fewer than 4 bowel movements per week will discontinue study therapy
PROJECTED ACCRUAL Approximately 600 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P30CA006516 | NIH | None | None |
| DFCI-NAL-0597 | None | None | None |
| BWH-1999-P-00241510 | None | None | None |
| BWH-97-08658 | None | None | None |
| ROXANE-NAL-0597 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA006516 |